erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
.
.; author, dr. barbara starfield, revered public health expert at the johns hopkins school of public health; �is us health really the best in the world?�
.
"there may be subtle differences (between animals and humans) that we don't know about," klein said.
.
.
.